Loading
Two large trials found radioactive beads were gentler than sorafenib but did not help patients live longer.
SARAH and SIRveNIB, led by trial NCT01482442 and sponsored by AP-HP and the National Cancer Centre Singapore, were two large trials reported in 2017 that found yttrium-90 radioembolisation was gentler than sorafenib in locally advanced hepatocellular carcinoma but did not help patients live longer. SARAH randomised 459 patients and SIRveNIB 360, and neither improved overall survival, although the radioactive beads gave better quality of life and more responses. OnCo links them to hepatocellular carcinoma, radioembolisation and sorafenib. The results were interpreted as showing the need for personalised dosimetry and earlier-stage use rather than the failure of the modality, and whether dosimetry-guided radioembolisation can succeed where fixed dosing did not is the open question.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Hepatocellular carcinoma and the tag failure.
Shares Hepatocellular carcinoma and the tag failure.
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
Shares Sorafenib, Hepatocellular carcinoma.
Shares Sorafenib, Hepatocellular carcinoma.
Shares Sorafenib, Hepatocellular carcinoma.
Shares Sorafenib, Hepatocellular carcinoma.
Shares Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.